UroGen Pharma Ltd. — Director's Dealing 2019

Jan 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: FALBERG KATHRYN E (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$13.00	2027-05-03	Ordinary Shares (40000)		Direct
Stock Option (right to buy)	$59.23	2028-06-04	Ordinary Shares (10000)		Direct

Footnotes

F1: 8.33% of the shares underlying the stock option shall vest in equal quarterly installments commencing 3 months after May 3, 2017.

F2: 25% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will vest 25% on each of March 4, 2019 and June 4, 2019.